FDA Brief

Warning letters Drugs

FDA warning letter to

Green Pharmaceuticals Inc.

High riskIssued Dec 16, 2022Posted Dec 27, 2022Division of Pharmaceutical Quality Operations IV

FDA found Green Pharmaceuticals' SnoreStop NasoSpray contaminated with Providencia rettgeri and sold as an unapproved new drug.

What happened

FDA laboratory testing of a batch of SnoreStop NasoSpray (lot 2373/21222) found gross microbial contamination, including Providencia rettgeri, with total aerobic counts from 420 to 6,200 CFU/mL and yeast/mold counts from 30 to 3,800 CFU/mL. After a June 2, 2022 teleconference and review of records, FDA determined the firm's manufacturing methods, facilities, or controls did not conform to CGMP; the firm said it did not test finished products for objectionable microorganisms before release and relied on its contract manufacturer's certificate of analysis. FDA also found the product label made it an unapproved new drug for snoring.

What FDA found

  1. A sample of lot 2373/21222 had gross microbial contamination and was contaminated with Providencia rettgeri.

    section 501(a)(1) of the FD&C Act, 21 U.S.C. 351(a)(1)
  2. FDA determined from the firm's records that its methods, facilities, or controls for manufacturing did not conform to CGMP.

    section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B)
  3. The firm released finished drug product without testing each batch for objectionable microorganisms and relied on the contract manufacturer's certificate of analysis.

    21 CFR 211.165(b); section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B)
  4. SnoreStop was marketed as a homeopathic anti-snoring drug without an FDA-approved application.

    sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)

What FDA wants

FDA asks the firm to correct the violations promptly and respond in writing within 15 working days with corrective actions and the requested microbiology, manufacturing, risk-assessment, investigation, specification, test-method, and retain-sample testing information. FDA also recommends engaging a qualified CGMP consultant.

Who should pay attention

  • distributors and brands of OTC nasal sprays
  • drug companies that rely on contract manufacturers for release testing
  • quality teams handling microbial contamination and recalls

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk